Kornimate/medical-research-clean huggingface dataset:
psychometric evaluation of commonly used measures in stroke

Conditions: Stroke

Summary: purposes: the aim of this study is to examine the psychometric properties (e.g. test-retest reliability, random measurement error, practice effect, and responsiveness) of the commonly used measures in patients with stroke using medical record review. the investigators anticipate reviewing 1000 stroke patients' medical record from a medical center in taiwan. the medical record will be reviewed by an experienced and well-trained occupational therapist.

the investigators anticipate reviewing 1000 stroke patients' medical record (from 2018/6/1 to 2021/6/30) from a medical center in taiwan. the medical record will be reviewed by an experienced and well-trained occupational therapist. the study was approved by the local institutional review board. because the targeted populations for examining the test-retest reliability and responsiveness were different, the inclusion criteria were listed separately below. test-retest reliability chronic stroke patients' data was reviewed to examine the test-retest reliability. the participants met the following criteria: (1) diagnosis of cerebral hemorrhage or cerebral infarction, (2) age ≥ 20 years, and (3) stroke onset ≥ 6 months (first and recurrent stroke included). responsiveness subacute stroke patients' data was reviewed to examine the responsiveness. the participants met the following criteria: (1) diagnosis of cerebral hemorrhage or cerebral infarction, (2) age ≥ 20 years, and (3) stroke onset \< 3 months (first and recurrent stroke included).

Eligibility criteria:
inclusion criteria for test-retest reliability group (chronic stroke patients' medical record was reviewed to examine the test-retest reliability) : * cerebral hemorrhage or cerebral infarction. * age ≥ 20 years. * stroke onset ≥ 6 months (first and recurrent stroke included). inclusion criteria for responsiveness group (subacute stroke patients' medical record was reviewed to examine the responsiveness): * cerebral hemorrhage or cerebral infarction. * age ≥ 20 years. * stroke onset \< 3 months (first and recurrent stroke included). exclusion criteria • patients' diagnosis is not stroke.
study investigating tailored treatment with infliximab for active crohn's disease

Conditions: Crohn's Disease

Summary: to investigate whether sustained trough levels of ifx can be achieved using ifx (infliximab) trough level measurements and adjustment of dosing based upon these levels by means of two different standardized algorithms in comparison with 'standard of care' ifx treatment and its effects on clinical and endoscopic outcomes.


Eligibility criteria:
inclusion criteria: * age \> 18 years * active cd (cdai\>220) and signs of active inflammation as evidenced by elevated serum hscrp levels (\>5 mg/l) and/or elevated fecal calprotectin levels (\>250 µg/g) and endoscopically visible ulcers. * patients must be naïve to biologics with indication for starting anti-tnf therapy in accordance with national reimbursement criteria. * patients must be naïve to thiopurines or have failed therapy with thiopurines (in which case aza will be continued). * ongoing steroids are allowed if at stable dose for at least 2 weeks and at a maximum of prednisone 40 mg/d or budesonide 9 mg/day. * patients who consent to receiving infliximab 5 mg/kg at week 0, 2 and 6 and further on every 8 weeks in conjunction with azathioprine (2,5 mg/kg/day). patients who develop aza intolerance during the trial are continued in the trial without aza (ie ifx monotherapy). exclusion criteria: * absence of endoscopically visible ulcers * prior exposure to infliximab (other biologics allowed) * ongoing steroid therapy at doses \> 40 mg/d prednisolone equivalent * previous intolerance to azathioprine leading to drug discontinuation * ongoing infections * positive tuberculosis screen per local guidelines * serious other diseases including cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer * indication for immediate surgery * pregnant or breast-feeding woman. * positive fecal culture for salmonella, shigella, yersinia and campylobacter and/or presence of clostridium difficile b toxin in the stools * active tuberculosis * untreated latent tuberculosis (see national recommendations. appendix 2). * non-compliant subjects. * participation in another therapeutic study.

Keywords: crohn's disease ifx trough level
buprenorphine maintenance vs. detoxification in prescription opioid dependence

Conditions: Opiate Dependence

Summary: the aim of the study is to determine whether buprenorphine/naloxone maintenance versus detoxification using buprenorphine/naloxone, in prescription opioid dependent patients receiving primary care management and drug counseling in an office-based setting, leads to decreased illicit opioid use.

prescription opioid dependence is increasing and creates a significant public health burden, but office-based physicians lack evidence-based guidelines to decide between maintenance or detoxification treatment with buprenorphine/naloxone. the proposed study compares buprenorphine/naloxone maintenance (mtn) vs. detoxification (dtx) in a 18-week randomized clinical trail in a heterogeneous population of prescription opioid dependent patients (n=120) in a primary care clinic. patients are randomized to mtn or dtx after a 2-week induction period. mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (dc) and referral to ancillary services. dtx and mtn will be identical for the first 4 weeks (stabilization) following randomization. in mtn, buprenorphine/naloxone will continue unchanged for the remainder of the study. in dtx, the dosage of buprenorphine/naloxone will be tapered to zero over the next 3 weeks, and patients will not receive additional buprenorphine/naloxone for the remainder of the study. dtx patients will be offered thrice-weekly dc beginning during the taper and naltrexone will be offered 7 days following the last dose of bup. the study will test the hypothesis that mtn will lead to decreased illicit drug use and will demonstrate incremental cost-effectiveness compared to dtx. relevance to public health: the results of this study will help define the role of maintenance vs. detoxification with buprenorphine/naloxone in the care of prescription opioid dependent patients in primary care.

Eligibility criteria:
inclusion criteria: * opioid dependence exclusion criteria: * current dependence on alcohol, cocaine, benzodiazepines or sedatives * current suicide or homicide risk * current psychotic disorder or untreated major depression * inability to read or understand english * life-threatening or unstable medical problems

Keywords: buprenorphine buprenorphine/naloxone counseling primary care
r-chop + gm-csf for previously untreated lcl in elderly

Conditions: Lymphoma, Large B-Cell, Diffuse

Summary: patients will receive 6 to 8 cycles of r-chop (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with gm-csf.

the objective of this study is to estimate complete response rates for patients treated with this regimen, to assess overall response rates, event-free survival and overall survival; and to assess toxicities associated with r-chop + gm-csf. patients will receive 6 to 8 cycles of r-chop (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), with gm-csf.

Eligibility criteria:
inclusion criteria: * histologically confirmed, cd20+ b cell diffuse large cell lymphoma, with measurable or evaluable disease * having no prior chemotherapy, immunotherapy or radiotherapy except for one cycle of chop or r-chop. exclusion criteria: * pregnant * hepatitis b surface antigen positive * have known cns disease or hiv infection * have ny classification iii or iv disease.

Keywords: dlbcl, elderly previously untreated dlbcl in the elderly
fibrinogen concentrate in children cardiac surgery 2

Conditions: C.Surgical Procedure; Cardiac; Blood Coagulation Disorders; Hypofibrinogenemia

Summary: the purporse of this study is evaluate whether fibrinogen concentrate reduces postoperative bleeding in pediatric cardiac surgery with cardiopulmonary by-pass.

cardiac surgery in children may be associated with excessive perioperative bleeding. perioperative excessive bleeding is associated with need of transfusion with allogeneic blood products such as red blood cells, fresh frozen plasma, platelet pools, and cryoprecipitate. furthermore, bleeding may result in re-exploration, which is associated with increased morbidity and mortality.recent studies have shown that patients and children undergoing cardiac surgery with pump often experience a significant drop in their levels and function of fibrinogen, and it would be in part responsible for the bleeding. fibrinogen concentrate (haemocomplettan p)may reduce perioperative bleeding, requirements of blood transfusion and clinical outcomes in children undergoing cardiac surgery with pump.

Eligibility criteria:
inclusion criteria: * cardiac surgery with pump * written informed consent * age under 28 days of life or rachs-1 equal or greater than 3 or reoperation with age under 10 years exclusion criteria: * coagulopathy (inr \> 1.5) * low platelet count (lower than 100.000) * product or albumin allergy * active endocarditis * blalock-taussig * heart transplant * anemia (hemoglobin \< 10 g/dl) * impossibility to receive blood transfusion * hepatic dysfunction (total bilirubin \> 1.5 mg/dl) * known or suspected hypersensitivity to fibrinogen concentrate * thrombophilia or previous thrombosis * participation in another study

Keywords: cardiac surgical procedures fibrinogen bleeding
a non-invasive intervention (breestim) for management of phantom limb pain (plp) after limb amputation (experiment 1)

Conditions: Pain Management

Summary: the purpose of this study is to compare the effectiveness of innovative intervention of breathing controlled electrical stimulation (breestim) and conventional electrical stimulation (estim) in management of neuropathic phantom limb pain in patients after limb amputation.


Eligibility criteria:
inclusion criteria: * has phantom limb pain (plp) after amputation of one limb, upper or lower limb; * has chronic pain, \>3 months; * is stable on oral pain medications at least two weeks. (patients are allowed to continue their pain medications, i.e., no change in pain medications.) exclusion criteria: * currently adjusting oral pain medications for their plp; * has pain, but not plp (e.g., from inflammation at the incision wound of the residual limb); * has a pacemaker, or other metal and/or implanted devices; * has cognitive impairment from brain injury or are not able to follow commands, or to give consent; * has amputation in multiple limbs; * have asthma or other pulmonary diseases; * are not medically stable; * have preexisting psychiatric disorders; * alcohol or drug abuse; * have a history of seizures/epilepsy, or taking benzodiazepines, anticonvulsants, and antidepressants.

Keywords: phantom limb pain breestim
national register of oesophageal atresia

Conditions: Esophageal Atresia

Summary: the esophageal atresia is a group of birth defects including a break in continuity of the esophagus with or without persistent communication with the trachea (tracheoesophageal fistula), sometimes associated (from 50%) of other malformations (heart, kidney, digestive ...). the current prognosis for this ailment is good. however he persists a mortality (\<10%) and significant morbidity, firstly related malformations (heart, kidney, for example), and secondly with particularly difficult anatomical forms (forms long defect) . the prevalence of this condition is estimated to be 1/2500 in 3000 live births, making an estimated ± 2,500 new cases over to 10 years in france. the current project aims to set up a national registry (metropolitan france and dom tom) to measure the prevalence of esophageal atresia among live births, phenotypic characteristics, the circumstances of their diagnosis, and their initial future at short-term during the first year of life, at which time occurs the vast majority of deaths and complications in this disease.


Eligibility criteria:
inclusion criteria: * to be born in france * to have a esophageal atresia exclusion criteria: * to be born abroad

Keywords: esophageal atresia
efficacy study for sd device

Conditions: Overweight

Summary: the purpose of this study is to determine whether the sd unique device is effective in treatment of overweight and obesity.

obesity and overweight had become the number 1 health concern of the modern world. over 1 billion people worldwide are overweight or obese. those who suffer from overweight or obesity are exposed to other severe illnesses such as: diabetes, cardiovascular disease and cancer. only few drugs and surgeries are currently available as approved treatments for those who wish to reduce weight. the purpose of this study is to determine whether the sd unique medical device, is effective in treatment of overweight and obesity.

Eligibility criteria:
inclusion criteria: * bmi 30-41.99 * age 18-65 years exclusion criteria: * pregnant women, * type i and ii diabetes, * people with disfunctioning of thyroid gland * hypertension
a muti-center study comparing 3 procedures for bi-level cervical spondylosis

Conditions: Cervical Spondylosis

Summary: a muti-center study to compare the safety and efficacy of anterior cervical discectomy and fusion, cervical artificial disc replacement and hybrid surgery for bi-level cervical spondylosis.

patients with bi-level cervical spondylosis undergoing anterior cervical discectomy and fusion, cervical artificial disc replacement and hybrid surgery in the muti-center hospital were retrospectively reviewed.the safety and efficacy were evaluated based on scores of the neck disability index (ndi), visual analog scale (vas), and japanese orthopedic association (joa) and the range of motion of both operative segments and adjacent segments,not only in the preoperative,but also in the 5 days,6 months,12 months and the 5 years after surgery.

Eligibility criteria:
inclusion criteria: * (1) cervical degenerative pathology with symptomatic radiculopathy or myelopathy at two consecutive segments from c3 to c7 which not responding to conservative treatment for 6 weeks. (2) preoperative magnetic resonance imaging (mri), complete cervical spine radiography and computed tomography (ct) showed anterior compressive pathology. (3) none or slight osteophyte at the posterior edge of vertebrae. (4) none significant spinal stenosis or posterior compression. exclusion criteria: * ossification of the posterior longitudinal ligament (opll), tumor, fracture, infection, history of cervical spine surgery, narrowing of the spinal canal, and any serious general illness. cases with one or more than two segments requiring treatment were also excluded.

Keywords: hybrid surgery,acdf,c-adr,bi-level cervical spondylosis
serial ultrasound in metastatic renal cell carcinoma (mrcc)

Conditions: Kidney Cancer; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma

Summary: to assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment


Eligibility criteria:
inclusion criteria: * 18 years of age or older * pathology-confirmed diagnosis of metastatic rcc * at least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging * written informed consent. specific inclusion criteria: * arm 1: planned to be treated with combination of vegfr2 tyrosine kinase inhibitor (tki) plus immune checkpoint inhibitor (ici) * arm 2: planned to be treated with non-ici therapy exclusion criteria: -any comorbid condition that, in the opinion of the treating provider or the protocol directors, compromises the participant's ability to participate in the study
clinical application of cross-education during stroke rehabilitation

Conditions: Stroke

Summary: based on the current state of knowledge and gaps in the literature we will conduct an intervention study to explore novel treatment and rehabilitation of patients at royal university hospital (ruh) with motor deficits following stroke. this project has the following objectives: 1. to determine if cross-education, in addition to standard rehabilitation leads to better recovery of upper limb function for stroke patients with hemiparesis. 2. to incorporate functional brain activation as measured by functional magnetic resonance imaging (fmri) to examine the neural mechanisms associated with changes in motor function of the paretic arm post-stroke. 3. to use diffusion tensor imaging (dti) tractography to measure connectivity and examine the extent to which white matter tract thickness correlates with preserved motor output in patients post-stroke.


Eligibility criteria:
inclusion criteria: * 18 years or older * within 18 months of stroke recovery * medically stable * ambulatory * have moderate to severe upper limb hemiparesis as diagnosed by clinicians * consent exclusion criteria: * significant cognitive impairment or aphasia affecting understanding, as assessed by clinician * severe upper limb spasticity preventing any movement of the proximal arm and shoulder * diagnosis of hemorrhagic or bilateral stroke * history of other severe upper limb musculoskeletal injury * other neurological diseases * intracranial metal clips or cardiac pacemaker, or anything that would preclude an mri * any condition that would preclude the participant's ability to attend follow-up visits in the opinion of the investigator
thalamic lfps and vim dbs in essential tremor: correlation, evolution, and therapeutic perspectives

Conditions: Essential Tremor

Summary: the objective of this study is to characterize through spectral analysis intra-thalamic local field potentials (lfps) recorded through implanted dbs leads during periods with and without tremor in patients suffering from severe essential tremor.

essential tremor (et) is one of the most common adult movement disorders with a prevalence of 4% in the general population. although several medications (primidone, beta-adrenergic blockers, benzodiazepines...) are commonly used, few of them are truly effective for controlling the severe forms of et. since 1987, an alternative has emerged with the development of high frequency deep brain stimulation (dbs) of the thalamic nucleus ventralis intermedius (vim). this surgical technique now represents the gold standard treatment for tremor-disabled et patients. although vim-dbs is clearly effective for treatment of essential tremor (et) a partial loss of dbs effectiveness may occur over time in some patients. this loss of dbs effectiveness could be related to an adaptation of the local neuronal network to chronic stimulation (changes in synaptic plasticity). in order to avoid this problem, investigators plan to develop a intermittent mode of vim stimulation using a new medtronic device combining a dbs system with local field potential (lfps) sensing capability. first, investigators propose to analyse vim lfps in order to define a tremor biomarker in 10 patients operated for severe et. thereafter, investigators will automatically detect this biomarker using a specific algorithm and use it to trigger stimulation at the onset of tremor only. thus, this project will allow us to optimize dbs therapy in et, by improving the longevity of implantable devices and avoiding the loss of efficacy previously reported

Eligibility criteria:
inclusion criteria: * patients suffering from severe and disabling et with serious impact on their quality of life (qol). * 18-70 years old * free of evolutive and untreated psychiatric disorder * tremor must be predominant in the upper limbs although it can affect the lower limbs, head and voice. * affiliation to a social security system * written informed consent signed by the participant and the investigator (prior to any examination required by research) exclusion criteria: * parkinsonian tremor * pregnancy or lactating women * severe co-morbidity (cardiac, renal or respiratory failures, evolutive cancer) * impaired cognitive functions (score \<130 on mattis scale). * patients with severe atrophy or lesions on mri * depression (beck \> 10) * participation in another clinical research for 18 months (after surgery)

Keywords: essential tremor deep brain stimulation (dbs) ventral intermediate thalamus (vim) local field potentials (lfps) closed loop therapy
invasive ventilation strategies for neonates with acute respiratory distress syndrome syndrome (ards)

Conditions: Acute Respiratory Distress Syndrome; Bronchopulmonary Dysplasia; High Frequency Oscillation Ventilation

Summary: acute respiratory distress syndrome (ards) in neonates has been defined in 2017.the death rate is over 50%. hfov and cmv are two main invasive ventilation strategies. however, which one is better needing to be further elucidated.

severe acute respiratory distress syndrome (ards) is one of the serious complications in critically ill neonates. it can result in severe hypoxemia refractory to mechanical ventilation. usually, invasive ventilation with low parameters is enough for neonates with mild and moderate ards. and extracorporeal membrane oxygenation is used to neonates with severe ards. however, extracorporeal membrane oxygenation can also lead to high death rate and need more technique and conditions. mechanical ventilation with higher parameters was a substitute for such situations, but the death rate, complications and injuries of higher parameters is unknown. the purpose of the present study was to compare hfov with cmv as invasive respiratory support strategies on decrease the mortality and morbidities in neonate with ards.

Eligibility criteria:
inclusion criteria: * for a neonate to be included, the following four criteria must be fulfilled: (1)gestational age (ga) between 26+0 and 32+0 weeks (estimated on the postmenstrual date and early gestation ultrasonographic findings); (2)birth weight less than 2000g; (3) assisted with cmv within 12 h after birth; (4)diagnosis with ards and/or rds. (5)stabilization before randomization within 12 h after birth: fio2\ 7.20, paco2\<=60 mmhg, paw \<=7-8 cmh2o; exclusion criteria: * neonates with at least one of the following criteria are not eligible for the study: (1) neonates who only needed noninvasive ventilation; (2) major congenital anomalies or chromosomal abnormalities; (3) neuromuscular diseases; (4) upper respiratory tract abnormalities; (5) need for surgery known before the first extubation; (6) grade ⅲ-iv-intraventricular hemorrhage (ivh); (7) congenital lung diseases or malformations or pulmonary hypoplasia.
evaluation of an oral nutritional supplement containing an777

Conditions: Malnutrition; Sarcopenia

Summary: to evaluate the effect of an experimental oral nutritional supplement containing an777 compared to another oral nutritional supplement in a malnourished, elderly population.


Eligibility criteria:
inclusion criteria: subject (male or female) is \> or equal to 65 and \< or equal to 90 years of age subject is ambulatory subject has a subjective global assessment of b or c subject has gait speed \<0.8 m/s and/or low hand-grip strength subject has class 1 or class 2 sarcopenia subject agrees to refrain from starting a resistance exercise program exclusion criteria: subject has type 1 or type 2 diabetes subject has inflammatory disease with elevated high sensitivity c-reactive protein subject has renal function impairment subject reports gastrointestinal disorder (severe chronic diarrhea, nausea, vomiting) that would preclude ingestion of the study product; an obstruction of the gastrointestinal tract, inflammatory bowel disease; short bowel syndrome or other major gastrointestinal disease subject reports of current active malignant disease or other significant medical diagnoses. subject reports a history of allergy to any of the ingredients in the study products subject reports currently taking medications/dietary supplements/substances that could profoundly modulate metabolism or weight.